Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 5/20 | 0.46 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.46 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 8/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6490528 | 0.92 | DCTPP1 (0.42) | MRGPRX4SMN1; SMN2PPARGNR1H4 | |
| SCHEMBL6501562 | 0.92 | NR4A2 (0.57) | MRGPRX4NR4A2NR4A1NR4A3PPARG | |
| SCHEMBL6501198 | 0.89 | NR4A2 (0.48) | MRGPRX4NR4A2NR4A1NR4A3PPARG | |
| SCHEMBL7196400 | 0.87 | PIK3C2B (0.40) | MRGPRX4PPARG | |
| SCHEMBL6488966 | 0.86 | RXRA (0.41) | MRGPRX4NR4A2NR4A1NR4A3TP53 | |
| SCHEMBL7200216 | 0.86 | PIK3C2B (0.41) | MRGPRX4SMN1; SMN2NPC1RAB9A | |
| SCHEMBL6498814 | 0.86 | S1PR1 (0.39) | PPARG | |
| SCHEMBL6500949 | 0.84 | BCL2 (0.54) | MRGPRX4TP53PKMNFKB1NFKB2 | |
| SCHEMBL6489915 | 0.83 | NR4A2 (0.46) | MRGPRX4NR4A2NR4A1NR4A3SMN1; SMN2 | |
| SCHEMBL6501593 | 0.82 | KDM4C (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| WO-2004108686-A2 | BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | MRGPRX4 2443/4885NR4A2 2264/4885NR4A1 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.